As Provenge Sales Dip, Dendreon Hopes Restructuring Is The Answer
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite weaker sales of the cancer immunotherapy compared to the first quarter, the Seattle-based biotech insists it can stimulate demand.
You may also be interested in...
The Virtues Of Predictability: US Medicare’s Review Of Aduhelm Coverage
Medicare’s decision to initiate a formal review of coverage for the newly approved Alzheimer’s agent is a highly unsettling development in many respects. It is also probably the best possible news for Biogen and Eisai at this point.
No Happy Endings For Dendreon As It Closes Another Chapter
The once-hot biotech finally has filed for bankruptcy as it does its best to pay back note holders and looks to sell its floundering prostate cancer therapy in an effort to honor remaining employee contracts.
Shedding Earlier Fears, Pharma Takes A Fresh Look At Cell, Gene Therapies
The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.